Nature of the Event

This is a regulatory filing by Astonea Labs Limited to BSE Limited, confirming no deviation or variation in the utilization of proceeds from its Initial Public Offering (IPO) for the half-year ended 30th September 2026, as required under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details

  • Filing Authority: BSE Limited
  • Regulatory References: SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; SEBI Master Circular updated 30th January 2026; SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024

IPO Fund Utilization Status

  • Date of IPO Fund Raising: 30th May, 2025
  • Amount Raised: ₹37,66,50,000 (37.665 crore)
  • Financial Year: 2025-2026
  • Monitoring Agency: Not applicable
  • Deviation/Variation: No deviation or variation in use of funds from 1st April 2026 to 30th September 2026
  • Shareholder Approval: Not applicable (NA)
  • Explanation for Deviation: NIL
  • Audit Committee Comments: NIL
  • Auditors Comments: NIL

Breakdown of Fund Utilization as of 30th September 2026

| Object of Issue | Original Allocation (₹) | Revised Allocation (₹) | Amount Utilized (₹) | Unutilized Amount (₹) |

| Funding of expenses for registration in Bolivia | 1,28,97,000 | 75,00,000 | 8,34,230 | 66,65,770 |

| Purchase and installation of plant and machineries for ointment production | 5,23,40,000 | 3,00,57,814 | 3,00,57,814 | 0 (indicated by overline) |

| Advertising, marketing and brand building | 4,95,15,000 | 2,00,15,000 | 2,00,15,000 | 0 (indicated by overline) |

| Investment in procuring hardware and software | 68,38,000 | 15,44,825 | 15,44,825 | 0 (indicated by overline) |

| Funding of working capital requirements | 19,75,00,000 | 19,75,00,000 | 19,75,00,000 | 0 (indicated by overline) |

| General corporate purposes | 1,98,81,000 | 1,98,53,361 | 1,41,94,565 | 56,58,796 |

| Issue Expenses | 3,76,79,000 | 3,76,79,000 | 3,76,79,000 | 0 (indicated by overline) |

| Investment in Equity Stake of Damaira Pharmaceuticals Private Limited | 6,25,00,000 | 6,25,00,000 | 6,25,00,000 | Not specified (implied 0) |

Total: Original Allocation ₹37,66,50,000, Revised Allocation ₹37,66,50,000, Amount Utilized ₹36,43,25,434, Unutilized Amount ₹1,23,24,566

Additional Information

  • The company confirms no deviation or variation during the period, as per the note in the document.
  • The investment in Damaira Pharmaceuticals Private Limited is included in the utilization, with ₹6.25 crore allocated and utilized.
  • Signed by Ankit Kapoor, Company Secretary & Compliance Officer (Membership No. A75702).